Pharmaceutical Technology
OCTOBER 31, 2022
billion in 2031, at a compound annual growth rate (CAGR) of 4.4%. Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. The osteoarthritis (OA) market was valued at $2.5 of the 7MM sales, respectively.
The Thyroid Pharmacist
NOVEMBER 29, 2023
The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceutical companies are voluntary for supplement companies. We have 270 expiring in March 2025.) We have 299 expiring in March 2025.)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 10, 2023
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Capturing market share.
Pharmaceutical Technology
JUNE 19, 2023
Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide.
pharmaphorum
DECEMBER 6, 2022
Genetic testing companies, such as 23andMe , provide a service to check consumers’ genetic background, whilst also using the data gathered to collaborate with pharma companies on potential treatments. It is estimated that this will reach 70% by 2035. Industry interest.
ISPE
MARCH 6, 2023
link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceutical companies, purchased goods (e.g.,
Pharmaceutical Technology
MARCH 22, 2023
Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceutical companies. From 2025, it will be substituted with a new chapter on functional tests for the complete system.”
Expert insights. Personalized for you.
59 
Let's personalize your content